تقرير
The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports.
| العنوان: | The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports. |
|---|---|
| المؤلفون: | Colombo E; Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Gurizzan C; Division of Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, ASST Spedali Civili, Brescia, Italy., Ottini A; Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Caspani F; Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Bergamini C; Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Locati LD; Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Marchiselli C; Division of Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, ASST Spedali Civili, Brescia, Italy., Alberti A; Division of Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, ASST Spedali Civili, Brescia, Italy., Lorini L; Division of Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, ASST Spedali Civili, Brescia, Italy., Licitra LF; Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; Department of Oncology and Hematology , University of Milan, Milan, Italy., Bossi P; Division of Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, ASST Spedali Civili, Brescia, Italy.; Department of Oncology and Hematology , University of Brescia, Brescia, Italy., Resteghini C; Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. |
| المصدر: | Frontiers in oncology [Front Oncol] 2023 Feb 28; Vol. 13, pp. 1111146. Date of Electronic Publication: 2023 Feb 28 (Print Publication: 2023). |
| نوع المنشور: | Case Reports |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مستخلص: | Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) are the most frequent cancers in humans, with cumulative ultraviolet radiation exposure, aging, and immunodepression as the main risk factors. In most cases, these malignancies arise in the head and neck area, and they can be treated with locoregional therapies. A minority of cases require systemic therapy. Currently, Sonic Hedgehog inhibitors (i.e., vismodegib and sonidegib) have been approved for advanced BCC, while the PD-1 checkpoint inhibitor cemiplimab has been approved as a first-line treatment for cSCC and as a second-line treatment for BCC. Nevertheless, there is a clinical need for an effective and safe systemic therapies for advanced synchronous (syn) BCC/cSCC not amenable to local treatments. International guidelines do not provide specific recommendations for patients affected by this condition, and no case reports on the full-dose association of these medications have been previously reported. Here, we present the cases of two elderly patients affected by synBCC/cSCC of the head and neck, who received combined therapy with cemiplimab and sonidegib at full dose and standard schedule, achieving remarkable clinical benefit and long-term responses, without major adverse events. The instance of a feasible treatment for patients with advanced synBCC/cSCC will become increasingly frequent with the advancement of life expectancy in the global population, and the synergistic activity of targeted therapies and immunotherapy-administered either in association or sequentially-deserves to be further explored. Competing Interests: Author LDL received conference honoraria/advisory board fees from EISAI, MSD, Merck Serono, McCann Healthcare, Eli Lilly, Sanofi, Sunpharma, IPSEN, Bayer, and Roche. Author LL received occasional conference honoraria/advisory board fees from Astrazeneca, Bayer, MSD, Merck-Serono, AccMed, and Neutron Therapeutics, Inc. Author PB received advisory board or conference honoraria from Merck, Sanofi-Regeneron, Merck Sharp & Dohme, Sun Pharma, Angelini, Nestlè, and Elevar. Author CR received honoraria from SunPharma. None of these relationships interfere with the intellectual content in the current manuscript. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Colombo, Gurizzan, Ottini, Caspani, Bergamini, Locati, Marchiselli, Alberti, Lorini, Licitra, Bossi and Resteghini.) |
| References: | Adv Exp Med Biol. 2020;1268:123-139. (PMID: 32918216) Sci Rep. 2021 Feb 22;11(1):4337. (PMID: 33619293) Oncotarget. 2018 Dec 21;9(100):37439-37457. (PMID: 30647844) Clin Cancer Res. 2015 Mar 15;21(6):1289-97. (PMID: 25593302) Sci Rep. 2021 Jun 24;11(1):13206. (PMID: 34168209) J Clin Invest. 2019 Dec 2;129(12):5151-5162. (PMID: 31638600) Lancet Oncol. 2021 Jun;22(6):848-857. (PMID: 34000246) Lancet Oncol. 2020 Feb;21(2):294-305. (PMID: 31952975) Int J Mol Sci. 2020 Jul 29;21(15):. (PMID: 32751327) NPJ Genom Med. 2021 Jul 16;6(1):61. (PMID: 34272401) Br J Dermatol. 2020 Jun;182(6):1369-1378. (PMID: 31545507) J Eur Acad Dermatol Venereol. 2020 Sep;34(9):1944-1956. (PMID: 31990414) Arch Dermatol. 2000 Dec;136(12):1524-30. (PMID: 11115165) Cancer Treat Rev. 2020 Sep;89:102084. (PMID: 32738738) Cancer Immunol Res. 2019 Jun;7(6):866-873. (PMID: 31003990) CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338) Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-10. (PMID: 32207669) Br J Dermatol. 2017 Nov;177(5):1208-1216. (PMID: 28994104) Oral Oncol. 2020 Jan;100:104485. (PMID: 31821988) J Am Acad Dermatol. 2019 Feb;80(2):564-566. (PMID: 30145186) Genome Med. 2017 Apr 19;9(1):34. (PMID: 28420421) Oncoimmunology. 2017 Dec 22;7(3):e1404217. (PMID: 29399405) Sci Rep. 2018 Oct 24;8(1):15744. (PMID: 30356134) BMC Cancer. 2017 May 16;17(1):332. (PMID: 28511673) Australas J Dermatol. 2023 Feb;64(1):108-117. (PMID: 36269635) Eur J Cancer. 2022 Dec;177:103-111. (PMID: 36335780) Cancers (Basel). 2022 Sep 20;14(19):. (PMID: 36230474) Int J Mol Sci. 2017 Nov 22;18(11):. (PMID: 29165358) |
| فهرسة مساهمة: | Keywords: basal cell carcinoma; case report; checkpoint inhibitors; cutaneous squamous cell carcinoma; hedgehog inhibitors; immunotherapy; synchronous carcinomas |
| تواريخ الأحداث: | Date Created: 20230317 Latest Revision: 20230318 |
| رمز التحديث: | 20230320 |
| مُعرف محوري في PubMed: | PMC10013465 |
| DOI: | 10.3389/fonc.2023.1111146 |
| PMID: | 36925925 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2023.1111146 |